The Ongoing Journey of a Shigella Bioconjugate Vaccine

Shigellosis is a serious disease with a major impact, especially in low-income countries where mortality and morbidity are high. In addition, shigellosis among travelers and military personnel is a cause of significant morbidity and contributes to the increase in antimicrobial resistance. The World...

Full description

Saved in:
Bibliographic Details
Published in:Vaccines (Basel) Vol. 10; no. 2; p. 212
Main Authors: Martin, Patricia, Alaimo, Cristina
Format: Journal Article
Language:English
Published: Switzerland MDPI AG 29.01.2022
MDPI
Subjects:
Antibiotics
Antigens
Antimicrobial resistance
Bacteria
bioconjugate
Conjugates
Diarrhea
Drug resistance
Epidemics
Gram-positive bacteria
Health care
Immunogenicity
Low income areas
Microorganisms
Military personnel
Morbidity
O-antigen
Pathogens
Product development
Proteins
Public health
Review
Sanitation
Shigella
Shigellosis
Streptococcus infections
Vaccines
bioconjugate
O-antigen
vaccines
Shigella
ISSN:2076-393X, 2076-393X
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Shigellosis is a serious disease with a major impact, especially in low-income countries where mortality and morbidity are high. In addition, shigellosis among travelers and military personnel is a cause of significant morbidity and contributes to the increase in antimicrobial resistance. The World Health Organization (WHO) considers the development of a Shigella vaccine a priority for public health. Over the past 60 years, several efforts to develop a Shigella vaccine have been pursued, without success. The principle of preventing shigellosis with a conjugate vaccine was demonstrated in the 1990′s, but this vaccine was not further developed. Bioconjugation is an innovative technology that allows the production of conjugate vaccines in a biological environment to preserve native immunogenic structures. In this review, we describe the journey of the bioconjugate Shigella vaccine, one of the most advanced clinical programs for a Shigella vaccine.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:2076-393X
2076-393X
DOI:10.3390/vaccines10020212